- Industrial and healthcare sector manufacturer Scapa said it expected to post a 17% fall in first-half profit, owing to the loss of a key contract with ConvaTec.

Revenue for the six months through September grew 14.3%, or by 10.4% on a constant currency basis, the company said in a trading update.

The growth in revenue was predominantly driven by the healthcare division and a full period effect of the Systagenix technology transfer.

'The board considers Scapa to be well positioned to make further progress against its strategic, operational and financial objectives and remains confident in the group's outlook,' the company said.

Story provided by